Index RUT P/E - EPS (ttm) -3.15 Insider Own 43.28% Shs Outstand 91.50M Perf Week -12.83%
Market Cap 1.16B Forward P/E - EPS next Y -4.61 Insider Trans 3.08% Shs Float 59.64M Perf Month -17.39%
Income -270.00M PEG - EPS next Q -1.25 Inst Own 49.57% Short Float 10.70% Perf Quarter -23.28%
Sales 263.00M P/S 4.43 EPS this Y 17.81% Inst Trans 0.92% Short Ratio 8.03 Perf Half Y -37.39%
Book/sh 6.17 P/B 1.79 EPS next Y -35.03% ROA -22.10% Short Interest 6.38M Perf Year -33.31%
Cash/sh 10.36 P/C 1.07 EPS next 5Y -1.18% ROE -49.77% 52W Range 10.63 - 20.31 Perf YTD -25.65%
Dividend Est. - P/FCF - EPS past 5Y -23.70% ROI -44.12% 52W High -45.49% Beta 1.33
Dividend TTM - Quick Ratio 5.23 Sales past 5Y 186.11% Gross Margin 95.44% 52W Low 4.14% ATR (14) 0.77
Dividend Ex-Date - Current Ratio 5.23 EPS Y/Y TTM 21.18% Oper. Margin -113.31% RSI (14) 34.34 Volatility 9.34% 5.94%
Employees 577 Debt/Eq 0.10 Sales Y/Y TTM 119.80% Profit Margin -102.66% Recom 1.58 Target Price 30.70
Option/Short Yes / Yes LT Debt/Eq 0.08 EPS Q/Q -5.77% Payout - Rel Volume 1.56 Prev Close 10.74
Sales Surprise 23.23% EPS Surprise 5.33% Sales Q/Q 50.00% Earnings Nov 06 AMC Avg Volume 794.52K Price 11.07
SMA20 -11.74% SMA50 -21.92% SMA200 -29.02% Trades
Volume 1,238,479 Change 3.07%
Date
Action
Analyst
Rating Change
Price Target Change
Oct-21-24 Initiated H.C. Wainwright
Neutral
$20
Oct-08-24 Initiated Wells Fargo
Overweight
$29
Nov-18-22 Initiated BofA Securities
Neutral
$33
Oct-11-22 Initiated Morgan Stanley
Overweight
$40
Oct-15-21 Resumed BTIG Research
Buy
$57
Nov-24-20 Initiated Berenberg
Buy
$50
Nov-23-20 Initiated Evercore ISI
Outperform
Apr-03-20 Initiated Cantor Fitzgerald
Overweight
$21
Mar-04-20 Initiated Barclays
Overweight
$24
Nov-12-19 Initiated SunTrust
Buy
$20
Sep-27-19 Initiated Mizuho
Buy
$22
May-24-19 Resumed Citigroup
Buy
$25
Oct-09-18 Initiated Wedbush
Outperform
$22
Apr-09-18 Initiated Leerink Partners
Outperform
$21
Apr-09-18 Initiated Goldman
Neutral
$18
Apr-09-18 Initiated Citigroup
Buy
$18
Show Previous Ratings
Feb-18-25 08:40AM
06:57AM
06:52AM
Feb-15-25 03:45PM
Feb-11-25 04:35PM
05:00PM
Loading…
Feb-10-25 05:00PM
Jan-24-25 04:35PM
Jan-21-25 04:05PM
Dec-24-24 04:05PM
Dec-19-24 04:05PM
Dec-10-24 04:35PM
Dec-03-24 04:35PM
Dec-02-24 10:18AM
Nov-19-24 04:05PM
Nov-12-24 04:35PM
02:26AM
Loading…
Nov-07-24 02:26AM
Nov-06-24 05:35PM
04:22PM
Nov-05-24 09:00AM
07:48AM
Oct-30-24 10:01AM
09:00AM
Oct-24-24 04:35PM
07:30AM
Oct-22-24 04:05PM
Oct-17-24 03:02PM
Oct-09-24 06:03PM
04:35PM
08:00AM
Oct-02-24 04:05PM
04:35PM
Loading…
Sep-24-24 04:35PM
Sep-10-24 04:35PM
Aug-28-24 02:33PM
(Pharmaceutical Technology)
Aug-27-24 04:05PM
Aug-26-24 04:35PM
Aug-21-24 04:05PM
Aug-16-24 04:52AM
(Pharmaceutical Technology)
Aug-08-24 06:15PM
04:05PM
Aug-01-24 10:01AM
08:00AM
Jul-25-24 04:05PM
Jul-09-24 04:35PM
06:32AM
(Pharmaceutical Technology)
Jul-08-24 06:00PM
Jun-25-24 04:35PM
Jun-11-24 04:35PM
Jun-10-24 08:30AM
Jun-07-24 10:55AM
Jun-06-24 04:05PM
Jun-02-24 08:00AM
Jun-01-24 08:00AM
May-24-24 04:35PM
May-10-24 01:38PM
May-09-24 04:35PM
03:48PM
03:47AM
May-08-24 09:59PM
05:45PM
04:02PM
May-02-24 04:05PM
May-01-24 10:01AM
Apr-24-24 04:00PM
Apr-23-24 04:05PM
Apr-09-24 04:35PM
Mar-29-24 07:01PM
Mar-26-24 04:35PM
Mar-20-24 07:00PM
Mar-11-24 04:35PM
Feb-29-24 03:14AM
Feb-28-24 04:05PM
Feb-27-24 04:35PM
Feb-22-24 11:10AM
09:55AM
07:16AM
(Thomson Reuters StreetEvents)
Feb-21-24 04:37PM
04:05PM
Feb-09-24 04:35PM
Feb-07-24 05:00PM
Feb-05-24 12:59PM
Jan-29-24 05:00PM
Jan-26-24 04:35PM
Jan-16-24 05:00PM
Dec-11-23 04:35PM
Dec-04-23 08:00AM
Nov-27-23 04:35PM
Nov-14-23 04:00PM
Nov-13-23 04:35PM
Nov-08-23 04:05PM
Nov-07-23 04:01PM
Nov-06-23 05:00PM
Oct-31-23 10:01AM
Oct-24-23 04:35PM
Oct-17-23 04:00PM
Oct-10-23 04:35PM
Sep-27-23 05:14AM
Sep-26-23 04:35PM
Sep-11-23 04:35PM
Sep-05-23 07:37PM
Aug-24-23 04:35PM
Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
GILEAD SCIENCES, INC. 10% Owner Feb 18 '25 Buy 11.00 1,363,636 14,999,996 31,424,760 Feb 20 07:42 PM Goeltz II Robert C. Chief Financial Officer Dec 31 '24 Sale 15.00 3,594 53,910 60,138 Jan 03 04:08 PM Goeltz II Robert C. Officer Dec 31 '24 Proposed Sale 15.00 3,594 53,910 Dec 31 04:10 PM Azoy Alexander Chief Accounting Officer Dec 02 '24 Sale 15.32 201 3,079 19,070 Dec 04 04:10 PM Azoy Alexander Chief Accounting Officer Aug 13 '24 Sale 14.97 1,357 20,314 19,070 Aug 15 04:45 PM Jarrett Jennifer Chief Operating Officer Mar 27 '24 Sale 17.55 11,551 202,720 215,253 Mar 29 04:20 PM Jarrett Jennifer Chief Operating Officer Mar 18 '24 Sale 17.92 13,449 240,941 226,804 Mar 20 04:19 PM Jarrett Jennifer Chief Operating Officer Feb 27 '24 Sale 20.11 34,070 685,148 240,253 Feb 28 07:55 PM Jarrett Jennifer Chief Operating Officer Feb 26 '24 Sale 20.07 24,555 492,819 274,323 Feb 28 07:55 PM Jaen Juan C. President Feb 27 '24 Sale 20.10 23,132 464,953 1,188,233 Feb 28 07:55 PM Jaen Juan C. President Feb 26 '24 Sale 20.06 3,900 78,234 1,211,365 Feb 28 07:55 PM
Index - P/E - EPS (ttm) -7.14 Insider Own 47.32% Shs Outstand 6.35M Perf Week 1.15%
Market Cap 78.50M Forward P/E - EPS next Y -7.37 Insider Trans 48.21% Shs Float 3.35M Perf Month -17.39%
Income -40.80M PEG - EPS next Q -1.79 Inst Own 15.38% Short Float 0.41% Perf Quarter -22.03%
Sales 28.33M P/S 2.77 EPS this Y 49.51% Inst Trans 10.10% Short Ratio 0.41 Perf Half Y -14.89%
Book/sh 4.09 P/B 3.02 EPS next Y -9.10% ROA -53.73% Short Interest 0.01M Perf Year 11.16%
Cash/sh 14.94 P/C 0.83 EPS next 5Y 22.47% ROE -120.51% 52W Range 11.05 - 19.93 Perf YTD -21.74%
Dividend Est. - P/FCF 3.44 EPS past 5Y 22.47% ROI -156.24% 52W High -38.03% Beta 0.62
Dividend TTM - Quick Ratio 2.36 Sales past 5Y 50.86% Gross Margin 99.36% 52W Low 11.76% ATR (14) 0.81
Dividend Ex-Date - Current Ratio 2.36 EPS Y/Y TTM 58.31% Oper. Margin -163.94% RSI (14) 37.36 Volatility 7.29% 4.94%
Employees 65 Debt/Eq 0.06 Sales Y/Y TTM - Profit Margin -144.05% Recom 2.00 Target Price 36.00
Option/Short No / Yes LT Debt/Eq 0.00 EPS Q/Q 54.02% Payout - Rel Volume 0.63 Prev Close 12.75
Sales Surprise 18.70% EPS Surprise 34.44% Sales Q/Q - Earnings Nov 07 AMC Avg Volume 33.76K Price 12.35
SMA20 -8.28% SMA50 -15.79% SMA200 -19.03% Trades
Volume 21,152 Change -3.14%
Date
Action
Analyst
Rating Change
Price Target Change
Sep-20-24 Upgrade Jefferies
Hold → Buy
$2 → $35
Sep-13-21 Initiated H.C. Wainwright
Neutral
$3.50
Sep-02-21 Downgrade William Blair
Outperform → Mkt Perform
Mar-23-21 Downgrade SVB Leerink
Outperform → Mkt Perform
Nov-06-20 Downgrade Jefferies
Buy → Hold
$30 → $10
Oct-19-20 Initiated Truist
Buy
$55
Oct-16-19 Initiated Mizuho
Buy
$20
Nov-19-18 Initiated Leerink Partners
Outperform
$45
Oct-08-18 Upgrade B. Riley FBR
Neutral → Buy
$42
Aug-08-18 Initiated Robert W. Baird
Outperform
$74
Apr-13-18 Downgrade Chardan Capital Markets
Buy → Neutral
$35 → $50
Jan-05-18 Initiated B. Riley FBR, Inc.
Neutral
$35
Nov-08-17 Initiated Jefferies
Buy
$50
May-30-17 Initiated Chardan Capital Markets
Buy
$35
Show Previous Ratings
Feb-20-25 08:00AM
Dec-29-24 03:00AM
Dec-26-24 08:00AM
Dec-19-24 08:00AM
Nov-07-24 06:19PM
(Associated Press Finance) +5.11%
04:05PM
Loading…
04:05PM
Sep-23-24 01:39PM
08:00AM
Sep-16-24 09:40AM
Aug-08-24 05:22PM
(Associated Press Finance) +6.02%
04:05PM
Jul-15-24 08:00AM
Jun-18-24 08:00AM
Jun-17-24 08:00AM
Jun-10-24 08:00AM
08:00AM
Loading…
Jun-05-24 08:00AM
May-22-24 08:00AM
May-13-24 08:53AM
May-09-24 05:04AM
(Associated Press Finance)
May-08-24 04:05PM
Mar-28-24 10:53PM
04:05PM
Mar-25-24 12:52PM
Feb-08-24 08:00AM
Jan-04-24 08:00AM
Nov-10-23 04:05PM
08:00AM
Nov-08-23 05:08PM
(Associated Press Finance)
-12.48%
04:05PM
08:00AM
10:59AM
Loading…
Oct-17-23 10:59AM
07:00AM
Oct-11-23 08:00AM
Oct-02-23 08:00AM
Sep-19-23 04:05PM
Aug-09-23 06:11PM
(Associated Press Finance)
04:05PM
Jul-17-23 08:00AM
Jun-21-23 08:00AM
Jun-07-23 08:00AM
May-23-23 04:05PM
May-04-23 06:28PM
04:05PM
Apr-18-23 08:00AM
Mar-30-23 10:04AM
(Simply Wall St.) -10.11%
Mar-22-23 04:05PM
Feb-15-23 08:00AM
Dec-19-22 03:19PM
08:00AM
Nov-14-22 08:00AM
Nov-09-22 09:35AM
Nov-08-22 04:05PM
Nov-04-22 08:00AM
Oct-24-22 08:00AM
Oct-21-22 09:36AM
Oct-05-22 04:05PM
Aug-24-22 08:00AM
Aug-09-22 04:05PM
Aug-04-22 12:00PM
10:00AM
06:27AM
Jul-21-22 07:22AM
06:26AM
Jul-20-22 05:48PM
(American City Business Journals)
04:05PM
Jun-22-22 08:00AM
07:00AM
Jun-21-22 08:00AM
Jun-08-22 08:00AM
07:58AM
Jun-06-22 08:00AM
Jun-03-22 04:05PM
May-27-22 09:38AM
May-25-22 11:06AM
(American City Business Journals)
May-12-22 04:05PM
(GlobeNewswire) +7.41%
+6.21%
Apr-01-22 05:00PM
Mar-23-22 04:19PM
Mar-21-22 08:00AM
Mar-10-22 04:05PM
Feb-09-22 08:00AM
Jan-19-22 09:38PM
Jan-07-22 05:00PM
Jan-06-22 08:00AM
Jan-04-22 08:00AM
Dec-07-21 10:00AM
Dec-03-21 05:00PM
Nov-12-21 08:00AM
Nov-04-21 04:05PM
Nov-01-21 10:32AM
Oct-19-21 07:30AM
Oct-06-21 08:00AM
Oct-01-21 06:04PM
Sep-24-21 06:35AM
Sep-02-21 03:18PM
12:05PM
10:17AM
06:49AM
Sep-01-21 04:02PM
Aug-18-21 08:00AM
Aug-05-21 05:45PM
Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses on two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate. The company was founded by Uri Lopatin and Derek A. Small on October 7, 2005 and is headquartered in South San Francisco, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Houghton Michael Director Dec 30 '24 Buy 15.61 3,202 49,998 3,202 Dec 31 04:24 PM GILEAD SCIENCES, INC. 10% Owner Dec 19 '24 Buy 21.37 940,499 20,098,464 2,209,471 Dec 23 08:26 PM Schornstein Alexander 10% Owner Nov 22 '24 Buy 14.87 17,024 253,104 720,137 Nov 26 09:15 AM Schornstein Alexander 10% Owner Nov 25 '24 Buy 14.91 7,976 118,890 728,113 Nov 26 09:15 AM White Nicole S Chief Manufacturing Officer Nov 18 '24 Sale 16.29 40 652 11,871 Nov 19 04:05 PM Schornstein Alexander 10% Owner Oct 08 '24 Buy 14.58 10,000 145,800 703,113 Oct 09 09:15 AM White Nicole S Chief Manufacturing Officer Oct 03 '24 Sale 14.81 157 2,325 11,911 Oct 04 04:05 PM Okazaki Jason A CEO and President Oct 03 '24 Sale 14.81 197 2,918 14,904 Oct 04 04:05 PM White Nicole S Chief Manufacturing Officer Aug 02 '24 Sale 14.23 785 11,173 12,068 Aug 05 04:10 PM Okazaki Jason A CEO and President Aug 02 '24 Sale 14.23 981 13,962 15,101 Aug 05 04:05 PM Schornstein Alexander 10% Owner Jul 03 '24 Buy 12.29 4,562 56,067 688,675 Jul 08 10:48 AM Schornstein Alexander 10% Owner Jul 05 '24 Buy 12.52 4,438 55,564 693,113 Jul 08 10:48 AM Bjorkquist Jeanette M Principal Accounting Officer May 23 '24 Sale 14.93 24 358 3,142 May 24 04:10 PM McHutchison John G Director May 23 '24 Sale 14.93 2,117 31,615 19,104 May 24 04:10 PM White Nicole S Chief Manufacturing Officer May 23 '24 Sale 14.93 172 2,569 12,853 May 24 04:05 PM Okazaki Jason A CEO and President May 23 '24 Sale 14.93 549 8,199 16,082 May 24 04:05 PM White Nicole S Chief Manufacturing Officer Apr 30 '24 Sale 12.71 1,255 15,947 13,025 May 01 04:10 PM Okazaki Jason A CEO and President Apr 30 '24 Sale 12.71 1,569 19,937 16,423 May 01 04:05 PM McHutchison John G Director Apr 01 '24 Sale 13.07 1,206 15,765 21,221 Apr 02 04:25 PM Bjorkquist Jeanette M Principal Accounting Officer Apr 01 '24 Sale 13.07 114 1,490 3,166 Apr 02 04:20 PM White Nicole S Chief Manufacturing Officer Apr 01 '24 Sale 13.07 197 2,575 10,947 Apr 02 04:15 PM Okazaki Jason A CEO and President Apr 01 '24 Sale 13.07 354 4,627 13,826 Apr 02 04:05 PM Okazaki Jason A CEO and President Mar 27 '24 Sale 12.87 392 5,045 14,180 Mar 29 04:05 PM
Index - P/E - EPS (ttm) -1.72 Insider Own 61.68% Shs Outstand 43.96M Perf Week -27.91%
Market Cap 42.55M Forward P/E - EPS next Y -0.40 Insider Trans 6.62% Shs Float 16.85M Perf Month 4.48%
Income -62.80M PEG - EPS next Q -0.22 Inst Own 16.29% Short Float 1.18% Perf Quarter -4.35%
Sales 4.62M P/S 9.21 EPS this Y 59.04% Inst Trans 15.84% Short Ratio 0.05 Perf Half Y 3.16%
Book/sh 0.48 P/B 1.95 EPS next Y 64.85% ROA -82.36% Short Interest 0.20M Perf Year 68.75%
Cash/sh 1.34 P/C 0.69 EPS next 5Y 39.65% ROE -170.96% 52W Range 0.53 - 1.93 Perf YTD -2.62%
Dividend Est. - P/FCF - EPS past 5Y -44.91% ROI -222.41% 52W High -51.81% Beta -0.24
Dividend TTM - Quick Ratio 1.67 Sales past 5Y 0.00% Gross Margin 62.40% 52W Low 74.16% ATR (14) 0.17
Dividend Ex-Date - Current Ratio 1.67 EPS Y/Y TTM 41.89% Oper. Margin -1388.44% RSI (14) 48.99 Volatility 17.80% 12.88%
Employees 73 Debt/Eq 0.40 Sales Y/Y TTM - Profit Margin -1359.37% Recom 1.33 Target Price 4.50
Option/Short No / Yes LT Debt/Eq 0.35 EPS Q/Q 63.70% Payout - Rel Volume 0.85 Prev Close 1.06
Sales Surprise -30.91% EPS Surprise 10.82% Sales Q/Q - Earnings Nov 07 BMO Avg Volume 3.94M Price 0.93
SMA20 7.43% SMA50 -4.19% SMA200 -2.85% Trades
Volume 3,360,714 Change -12.26%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-21-22 Initiated Chardan Capital Markets
Buy
$7
Jan-10-22 Initiated H.C. Wainwright
Buy
$36
Nov-16-21 Initiated Raymond James
Outperform
$31
Nov-16-21 Initiated Morgan Stanley
Overweight
$32
Nov-16-21 Initiated Guggenheim
Buy
$40
Nov-16-21 Initiated Cowen
Outperform
Feb-13-25 04:17AM
(Pharmaceutical Technology) -12.84%
Feb-12-25 10:44AM
07:35AM
07:33AM
Feb-03-25 04:30PM
09:00AM
Loading…
Jan-22-25 09:00AM
Jan-21-25 05:05PM
Jan-17-25 04:30PM
Jan-10-25 05:00PM
Dec-19-24 07:30AM
Dec-16-24 07:30AM
Dec-09-24 09:55AM
Dec-03-24 04:30PM
Nov-07-24 09:15AM
09:05AM
09:01AM
Loading…
Oct-30-24 09:01AM
Oct-04-24 09:05AM
Oct-02-24 04:15PM
Aug-28-24 04:01PM
Aug-08-24 07:30AM
Jun-13-24 04:05PM
May-29-24 06:05AM
(Pharmaceutical Technology)
May-14-24 01:54PM
07:30AM
Apr-16-24 09:14AM
Apr-01-24 10:53PM
04:05PM
Mar-28-24 11:10AM
07:05AM
07:00AM
06:45AM
Loading…
06:45AM
Feb-28-24 04:01PM
(GlobeNewswire) +5.60%
+7.42%
Jan-31-24 04:01PM
Jan-08-24 07:30AM
Dec-07-23 07:30AM
Nov-09-23 04:01PM
(GlobeNewswire) -13.04%
-10.63%
Nov-03-23 12:00PM
Oct-31-23 09:15AM
Sep-27-23 05:02PM
Sep-05-23 08:30AM
07:30AM
Aug-18-23 04:27AM
(Thomson Reuters StreetEvents)
Aug-14-23 07:30AM
Aug-03-23 04:05PM
May-25-23 05:01PM
May-09-23 07:30AM
Apr-03-23 04:05PM
Mar-02-23 04:05PM
Feb-27-23 07:30AM
Feb-16-23 07:30AM
Feb-02-23 07:30AM
Jan-26-23 05:30AM
Jan-25-23 09:45AM
Nov-23-22 07:30AM
Nov-09-22 07:30AM
Nov-04-22 07:30AM
Sep-22-22 04:05PM
Sep-15-22 04:05PM
Sep-06-22 04:05PM
Aug-11-22 09:41AM
Aug-09-22 07:30AM
Jun-16-22 07:30AM
May-18-22 07:30AM
May-17-22 07:30AM
May-12-22 07:30AM
Apr-07-22 06:30AM
Mar-01-22 06:30AM
Feb-28-22 06:30AM
Feb-07-22 05:38PM
Feb-03-22 06:30AM
Jan-25-22 10:27AM
Jan-20-22 07:30AM
Jan-06-22 07:30AM
Dec-02-21 07:30AM
Nov-12-21 07:00AM
Oct-27-21 07:45AM
Oct-26-21 04:05PM
Xilio Therapeutics, Inc. operates as a biotechnology company. It focuses on harnessing the immune system to achieve deep and durable clinical responses in cancer. The company uses its proprietary geographically precise solutions platform to rapidly engineer novel molecules, including cytokines and other biologics. Xilio Therapeutics was founded by John C. Williams and Ulrich Rodeck in June 2015 and is headquartered in Waltham, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Frankenfield Christopher James Chief Financial Officer Jan 02 '25 Sale 0.98 6,954 6,841 12,421 Jan 03 04:15 PM Brennan Kevin M. SVP, FINANCE AND ACCOUNTING Jan 02 '25 Sale 0.98 1,803 1,774 3,197 Jan 03 04:15 PM GILEAD SCIENCES, INC. 10% Owner Dec 18 '24 Buy 1.04 1,759,978 1,830,377 9,105,451 Dec 19 04:19 PM GILEAD SCIENCES, INC. 10% Owner Apr 02 '24 Buy 0.76 485,250 368,790 7,345,473 Apr 03 06:50 PM
Index RUT P/E - EPS (ttm) -3.07 Insider Own 55.89% Shs Outstand 43.17M Perf Week -8.55%
Market Cap 120.02M Forward P/E - EPS next Y -3.70 Insider Trans 0.00% Shs Float 19.04M Perf Month -15.50%
Income -110.66M PEG - EPS next Q -0.84 Inst Own 32.74% Short Float 14.63% Perf Quarter -36.89%
Sales 0.00M P/S - EPS this Y 96.32% Inst Trans -1.56% Short Ratio 7.00 Perf Half Y -62.48%
Book/sh 7.01 P/B 0.40 EPS next Y -12.14% ROA - Short Interest 2.79M Perf Year -90.15%
Cash/sh 7.45 P/C 0.37 EPS next 5Y 66.11% ROE - 52W Range 2.64 - 30.60 Perf YTD -25.67%
Dividend Est. - P/FCF - EPS past 5Y - ROI -35.94% 52W High -90.92% Beta 2.97
Dividend TTM - Quick Ratio 10.50 Sales past 5Y -37.90% Gross Margin - 52W Low 5.10% ATR (14) 0.27
Dividend Ex-Date - Current Ratio 10.50 EPS Y/Y TTM - Oper. Margin - RSI (14) 36.43 Volatility 7.52% 9.23%
Employees 96 Debt/Eq 0.03 Sales Y/Y TTM - Profit Margin - Recom 1.29 Target Price 20.67
Option/Short Yes / Yes LT Debt/Eq 0.02 EPS Q/Q -122.75% Payout - Rel Volume 0.86 Prev Close 2.84
Sales Surprise - EPS Surprise 1.76% Sales Q/Q - Earnings Nov 13 AMC Avg Volume 397.87K Price 2.78
SMA20 -10.68% SMA50 -22.01% SMA200 -59.58% Trades
Volume 343,615 Change -2.11%
Date
Action
Analyst
Rating Change
Price Target Change
Oct-10-24 Initiated UBS
Buy
$13
Oct-09-24 Initiated Rodman & Renshaw
Buy
$16
Jul-03-24 Initiated H.C. Wainwright
Neutral
$8
Mar-04-24 Initiated Wells Fargo
Overweight
$44
Mar-04-24 Initiated Morgan Stanley
Overweight
$40
Mar-04-24 Initiated Leerink Partners
Outperform
$48
Mar-04-24 Initiated JP Morgan
Overweight
$39
Feb-10-25 12:00PM
Jan-21-25 04:05PM
Jan-17-25 05:45AM
Jan-13-25 07:30AM
Jan-08-25 08:00AM
05:45AM
Loading…
Jan-07-25 05:45AM
Jan-06-25 04:05PM
Dec-27-24 05:45AM
Dec-19-24 12:16PM
Dec-13-24 04:05PM
Dec-09-24 06:38PM
(GlobeNewswire) +6.81%
-5.56%
Nov-14-24 10:01AM
Nov-13-24 04:14PM
Oct-21-24 08:00AM
Oct-19-24 11:13AM
03:05PM
Loading…
Oct-10-24 03:05PM
Sep-18-24 08:00AM
Sep-16-24 08:00AM
06:58AM
Aug-21-24 04:05PM
(PR Newswire) +13.36%
-5.36%
Aug-12-24 04:08PM
04:05PM
Jul-16-24 11:33AM
(Pharmaceutical Technology) +11.71%
08:52AM
Jul-15-24 04:05PM
Jun-20-24 08:55AM
Jun-17-24 04:05PM
(PR Newswire) -17.21%
-5.70%
Jun-10-24 04:05PM
Jun-07-24 08:55AM
May-14-24 10:54PM
04:05PM
Loading…
04:05PM
Apr-11-24 05:01PM
Mar-29-24 02:59PM
Mar-26-24 04:05PM
Mar-14-24 07:00AM
(The Wall Street Journal)
Mar-07-24 07:26PM
06:14PM
Feb-12-24 04:39PM
Feb-07-24 10:29PM
Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company. It develops treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Walker Karen Marie Chief Technology Officer Jun 06 '24 Option Exercise 4.42 9,636 42,591 9,636 Jun 10 06:56 PM Jones Ryan Alexander Chief Financial Officer May 28 '24 Option Exercise 0.73 18,016 13,152 43,950 May 29 04:33 PM
Index - P/E - EPS (ttm) -20.16 Insider Own 54.38% Shs Outstand 5.02M Perf Week -2.53%
Market Cap 29.63M Forward P/E - EPS next Y - Insider Trans -3.38% Shs Float 2.30M Perf Month 4.67%
Income -100.20M PEG - EPS next Q - Inst Own 22.70% Short Float 2.59% Perf Quarter -27.69%
Sales 0.00M P/S - EPS this Y - Inst Trans -49.80% Short Ratio 2.48 Perf Half Y -44.51%
Book/sh 24.13 P/B 0.40 EPS next Y - ROA -54.04% Short Interest 0.06M Perf Year -40.51%
Cash/sh 39.60 P/C 0.24 EPS next 5Y - ROE -63.33% 52W Range 7.96 - 24.15 Perf YTD -0.31%
Dividend Est. - P/FCF - EPS past 5Y -70.97% ROI -82.73% 52W High -60.12% Beta 0.64
Dividend TTM - Quick Ratio 86.78 Sales past 5Y -25.00% Gross Margin - 52W Low 20.98% ATR (14) 0.63
Dividend Ex-Date - Current Ratio 86.78 EPS Y/Y TTM 48.98% Oper. Margin - RSI (14) 45.63 Volatility 4.08% 5.45%
Employees 112 Debt/Eq 0.00 Sales Y/Y TTM - Profit Margin - Recom 4.00 Target Price 20.70
Option/Short No / Yes LT Debt/Eq 0.00 EPS Q/Q 90.80% Payout - Rel Volume 0.21 Prev Close 9.83
Sales Surprise - EPS Surprise -66.26% Sales Q/Q - Earnings Aug 01 Avg Volume 23.96K Price 9.63
SMA20 -2.24% SMA50 -4.48% SMA200 -37.68% Trades
Volume 5,095 Change -2.03%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-26-23 Downgrade BofA Securities
Buy → Underperform
$17 → $1
Dec-22-23 Downgrade Piper Sandler
Overweight → Neutral
Dec-22-23 Downgrade Leerink Partners
Outperform → Market Perform
Dec-22-23 Downgrade JP Morgan
Overweight → Underweight
Aug-18-23 Initiated BofA Securities
Buy
$17
Oct-19-21 Resumed Morgan Stanley
Overweight
$48
Aug-24-20 Initiated SVB Leerink
Outperform
$41
Aug-24-20 Initiated Morgan Stanley
Overweight
$49
Aug-24-20 Initiated JP Morgan
Overweight
$50
Nov-11-24 10:44AM
(Pharmaceutical Technology) +19.39%
Nov-08-24 07:04AM
06:00AM
Oct-11-24 07:02PM
Aug-09-24 02:52PM
08:53AM
Loading…
May-14-24 08:53AM
Mar-18-24 03:53PM
Mar-13-24 11:53AM
10:00AM
Mar-12-24 05:50AM
Mar-06-24 06:17PM
Mar-04-24 05:37PM
Feb-28-24 01:06AM
Feb-27-24 08:00AM
Feb-26-24 12:27PM
10:30AM
Loading…
Feb-23-24 10:30AM
Jan-29-24 09:40AM
Jan-24-24 09:45AM
Jan-12-24 09:35AM
Jan-05-24 11:03AM
08:37AM
Dec-26-23 10:04AM
Dec-22-23 09:31AM
08:30AM
07:10AM
07:00AM
Dec-05-23 08:55AM
Nov-16-23 07:00AM
Nov-02-23 10:04AM
07:00AM
02:44PM
Loading…
Sep-21-23 02:44PM
Sep-14-23 09:59AM
Aug-28-23 07:00AM
Aug-03-23 07:00AM
Jul-21-23 07:17AM
Jul-12-23 03:12AM
Jul-04-23 07:34AM
Jul-03-23 03:59AM
Jun-27-23 12:00PM
Jun-23-23 01:56PM
Jun-21-23 09:20PM
04:18PM
Jun-09-23 11:04AM
Jun-05-23 07:00AM
May-16-23 07:00AM
May-04-23 07:00AM
May-01-23 07:00AM
Apr-26-23 05:12PM
07:00AM
Mar-30-23 11:12AM
Feb-23-23 04:15PM
Feb-15-23 10:05AM
07:07AM
07:00AM
Feb-10-23 09:55AM
Feb-07-23 10:17AM
Feb-01-23 07:00AM
Jan-25-23 12:00PM
09:55AM
09:40AM
Jan-09-23 07:00AM
Jan-03-23 07:00AM
Dec-10-22 05:15PM
Nov-15-22 07:00AM
Nov-03-22 09:07AM
07:00AM
Oct-21-22 08:30AM
Sep-06-22 09:55AM
Aug-31-22 07:00AM
Aug-19-22 09:55AM
Aug-04-22 07:00AM
Aug-03-22 09:55AM
Aug-01-22 08:09AM
Jul-27-22 07:00AM
Jun-07-22 12:07PM
08:30AM
May-05-22 07:00AM
Apr-21-22 11:35AM
Apr-20-22 07:00AM
Apr-04-22 07:40PM
Mar-31-22 07:00AM
Mar-23-22 09:56AM
Mar-22-22 07:00AM
Feb-11-22 07:00AM
Feb-10-22 07:00AM
Jan-05-22 07:30AM
Jan-03-22 04:05PM
Dec-16-21 04:05PM
Dec-11-21 01:00PM
Nov-17-21 11:57AM
Nov-15-21 07:00AM
Nov-10-21 11:48AM
Nov-05-21 07:00AM
Oct-29-21 09:47AM
Oct-06-21 11:31AM
Oct-05-21 06:48AM
Oct-04-21 07:00AM
Sep-29-21 02:09PM
07:00AM
Sep-07-21 07:00AM
AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Miller Edward General Counsel Jan 23 '25 Sale 9.50 52 494 6,623 Jan 27 04:16 PM Hagen Brett R Chief Accounting Officer Jan 23 '25 Sale 9.51 36 342 2,928 Jan 27 04:15 PM Sinha Vikas See Remarks Jan 23 '25 Sale 9.50 129 1,226 49,432 Jan 27 04:11 PM Sinha Vikas Owner Jan 23 '25 Proposed Sale 9.55 129 1,232 Jan 24 03:03 PM Miller Edward Officer Jan 23 '25 Proposed Sale 9.52 52 495 Jan 24 02:55 PM Hagen Brett R Officer Jan 23 '25 Proposed Sale 9.47 36 341 Jan 24 02:51 PM Miller Edward General Counsel Jan 10 '25 Sale 0.44 409 180 153,541 Jan 13 04:15 PM Hagen Brett R Chief Accounting Officer Jan 10 '25 Sale 0.44 332 146 68,174 Jan 13 04:15 PM Sinha Vikas See Remarks Jan 10 '25 Sale 0.44 979 431 1,139,915 Jan 13 04:15 PM Miller Edward Officer Jan 10 '25 Proposed Sale 0.44 409 180 Jan 10 08:00 PM Sinha Vikas Owner Jan 10 '25 Proposed Sale 0.44 979 431 Jan 10 08:00 PM Hagen Brett R Officer Jan 10 '25 Proposed Sale 0.44 332 146 Jan 10 08:00 PM Hagen Brett R Chief Accounting Officer Nov 19 '24 Sale 0.55 554 304 68,506 Nov 20 04:15 PM Sinha Vikas See Remarks Nov 19 '24 Sale 0.55 3,186 1,748 1,140,894 Nov 20 04:15 PM Miller Edward General Counsel Nov 19 '24 Sale 0.55 432 237 211,499 Nov 20 04:15 PM Brainard Diana Chief Executive Officer Nov 19 '24 Sale 0.55 8,706 4,775 723,363 Nov 20 04:15 PM Sinha Vikas Owner Nov 19 '24 Proposed Sale 0.54 3,186 1,735 Nov 19 08:00 PM Miller Edward Officer Nov 19 '24 Proposed Sale 0.54 432 235 Nov 19 08:00 PM Brainard Diana Officer Nov 19 '24 Proposed Sale 0.55 8,706 4,763 Nov 19 08:00 PM Hagen Brett R Officer Nov 19 '24 Proposed Sale 0.55 554 302 Nov 19 08:00 PM Brainard Diana Chief Executive Officer Nov 05 '24 Sale 0.86 10,609 9,176 732,069 Nov 06 04:15 PM Miller Edward General Counsel Nov 05 '24 Sale 0.86 2,272 1,965 211,931 Nov 06 04:15 PM Hagen Brett R Chief Accounting Officer Nov 05 '24 Sale 0.86 1,655 1,431 69,060 Nov 06 04:15 PM Sinha Vikas See Remarks Nov 05 '24 Sale 0.86 5,136 4,442 1,144,080 Nov 06 04:15 PM Brainard Diana Officer Nov 05 '24 Proposed Sale 0.86 10,609 9,176 Nov 05 08:00 PM Miller Edward Officer Nov 05 '24 Proposed Sale 0.86 2,272 1,965 Nov 05 08:00 PM Hagen Brett R Officer Nov 05 '24 Proposed Sale 0.86 1,655 1,431 Nov 05 08:00 PM Sinha Vikas Owner Nov 05 '24 Proposed Sale 0.86 5,136 4,442 Nov 05 08:00 PM Brainard Diana Chief Executive Officer Oct 21 '24 Sale 0.78 9,752 7,597 742,678 Oct 23 04:15 PM Sinha Vikas See Remarks Oct 22 '24 Sale 0.77 1,882 1,445 1,149,216 Oct 23 04:15 PM Sinha Vikas See Remarks Oct 21 '24 Sale 0.78 1,546 1,204 1,151,098 Oct 23 04:15 PM Hagen Brett R Chief Accounting Officer Oct 22 '24 Sale 0.77 486 373 70,715 Oct 23 04:15 PM Hagen Brett R Chief Accounting Officer Oct 21 '24 Sale 0.78 479 373 71,201 Oct 23 04:15 PM Miller Edward General Counsel Oct 22 '24 Sale 0.77 766 588 214,203 Oct 23 04:15 PM Miller Edward General Counsel Oct 21 '24 Sale 0.78 635 495 214,969 Oct 23 04:15 PM Hagen Brett R Officer Oct 22 '24 Proposed Sale 0.77 486 373 Oct 22 08:00 PM Miller Edward Officer Oct 22 '24 Proposed Sale 0.77 766 588 Oct 22 08:00 PM Sinha Vikas Owner Oct 22 '24 Proposed Sale 0.77 1,882 1,445 Oct 22 08:00 PM Sinha Vikas Owner Oct 21 '24 Proposed Sale 0.78 1,546 1,204 Oct 21 08:00 PM Hagen Brett R Officer Oct 21 '24 Proposed Sale 0.78 479 373 Oct 21 08:00 PM Brainard Diana Officer Oct 21 '24 Proposed Sale 0.78 9,752 7,596 Oct 21 08:00 PM Miller Edward Officer Oct 21 '24 Proposed Sale 0.78 635 495 Oct 21 08:00 PM Sinha Vikas See Remarks Oct 03 '24 Sale 0.81 940 766 1,152,644 Oct 04 04:15 PM Miller Edward General Counsel Oct 03 '24 Sale 0.81 377 307 215,604 Oct 04 04:15 PM Brainard Diana Chief Executive Officer Oct 03 '24 Sale 0.81 1,493 1,216 752,430 Oct 04 04:15 PM Hagen Brett R Chief Accounting Officer Oct 03 '24 Sale 0.81 301 245 71,680 Oct 04 04:15 PM Brainard Diana Officer Oct 03 '24 Proposed Sale 0.81 1,493 1,216 Oct 03 08:00 PM Sinha Vikas Owner Oct 03 '24 Proposed Sale 0.81 940 766 Oct 03 08:00 PM Miller Edward Officer Oct 03 '24 Proposed Sale 0.81 377 307 Oct 03 08:00 PM Hagen Brett R Officer Oct 03 '24 Proposed Sale 0.81 301 245 Oct 03 08:00 PM Brainard Diana Chief Executive Officer Aug 20 '24 Sale 0.74 5,390 3,996 753,923 Aug 22 04:15 PM Brainard Diana Officer Aug 20 '24 Proposed Sale 0.74 5,390 3,996 Aug 21 11:14 AM Miller Edward General Counsel Aug 19 '24 Sale 0.76 422 321 215,981 Aug 20 04:15 PM Sinha Vikas See Remarks Aug 19 '24 Sale 0.76 3,159 2,399 1,153,584 Aug 20 04:15 PM Hagen Brett R Chief Accounting Officer Aug 19 '24 Sale 0.76 544 413 71,981 Aug 20 04:15 PM Brainard Diana Chief Executive Officer Aug 19 '24 Sale 0.76 3,091 2,348 759,313 Aug 20 04:15 PM Sinha Vikas Owner Aug 19 '24 Proposed Sale 0.76 3,159 2,399 Aug 19 08:00 PM Brainard Diana Officer Aug 19 '24 Proposed Sale 0.76 3,091 2,348 Aug 19 08:00 PM Hagen Brett R Officer Aug 19 '24 Proposed Sale 0.76 544 413 Aug 19 08:00 PM Miller Edward Officer Aug 19 '24 Proposed Sale 0.76 422 321 Aug 19 08:00 PM Miller Edward General Counsel Aug 05 '24 Sale 0.73 2,323 1,707 216,403 Aug 07 04:15 PM Brainard Diana Chief Executive Officer Aug 05 '24 Sale 0.73 10,847 7,970 762,404 Aug 07 04:15 PM Sinha Vikas See Remarks Aug 05 '24 Sale 0.73 5,251 3,858 1,156,743 Aug 07 04:15 PM Hagen Brett R Chief Accounting Officer Aug 05 '24 Sale 0.73 1,692 1,243 72,525 Aug 07 04:15 PM Brainard Diana Officer Aug 05 '24 Proposed Sale 0.73 10,847 7,970 Aug 06 08:00 PM Sinha Vikas Owner Aug 05 '24 Proposed Sale 0.73 5,251 3,858 Aug 06 08:00 PM Hagen Brett R Officer Aug 05 '24 Proposed Sale 0.73 1,692 1,243 Aug 06 08:00 PM Miller Edward Officer Aug 05 '24 Proposed Sale 0.73 2,323 1,707 Aug 06 08:00 PM Hagen Brett R Chief Accounting Officer Jul 19 '24 Sale 0.75 479 359 74,698 Jul 23 04:28 PM Hagen Brett R Chief Accounting Officer Jul 22 '24 Sale 0.74 481 356 74,217 Jul 23 04:28 PM Brainard Diana Chief Executive Officer Jul 19 '24 Sale 0.75 9,731 7,299 773,251 Jul 23 04:28 PM Sinha Vikas See Remarks Jul 22 '24 Sale 0.74 1,858 1,373 1,161,994 Jul 23 04:27 PM Sinha Vikas See Remarks Jul 19 '24 Sale 0.75 1,542 1,157 1,163,852 Jul 23 04:27 PM Miller Edward General Counsel Jul 22 '24 Sale 0.74 757 560 218,726 Jul 23 04:25 PM Miller Edward General Counsel Jul 19 '24 Sale 0.75 634 476 219,483 Jul 23 04:25 PM Miller Edward General Counsel Jul 02 '24 Sale 0.72 379 273 220,117 Jul 03 04:14 PM Sinha Vikas See Remarks Jul 02 '24 Sale 0.72 939 676 1,165,394 Jul 03 04:14 PM Hagen Brett R Chief Accounting Officer Jul 02 '24 Sale 0.72 304 219 75,177 Jul 03 04:12 PM Brainard Diana Chief Executive Officer Jul 02 '24 Sale 0.72 1,489 1,072 782,982 Jul 03 04:11 PM Brainard Diana Chief Executive Officer May 21 '24 Sale 0.79 5,149 4,080 784,471 May 23 05:24 PM Hagen Brett R Chief Accounting Officer May 17 '24 Sale 0.75 541 405 75,481 May 21 04:35 PM Brainard Diana Chief Executive Officer May 17 '24 Sale 0.75 3,075 2,304 789,620 May 21 04:35 PM Sinha Vikas See Remarks May 17 '24 Sale 0.75 3,143 2,355 1,129,996 May 21 04:33 PM Miller Edward General Counsel May 17 '24 Sale 0.75 420 315 220,496 May 21 04:33 PM Brainard Diana Chief Executive Officer May 03 '24 Sale 0.80 10,240 8,151 792,695 May 07 04:15 PM Hagen Brett R Chief Accounting Officer May 03 '24 Sale 0.80 1,597 1,271 76,022 May 07 04:15 PM Sinha Vikas See Remarks May 03 '24 Sale 0.80 4,957 3,946 1,133,139 May 07 04:15 PM Miller Edward General Counsel May 03 '24 Sale 0.80 2,311 1,840 220,916 May 07 04:15 PM Hagen Brett R Chief Accounting Officer Apr 22 '24 Sale 0.75 480 360 77,619 Apr 23 04:15 PM Hagen Brett R Chief Accounting Officer Apr 19 '24 Sale 0.75 473 355 78,099 Apr 23 04:15 PM Miller Edward General Counsel Apr 22 '24 Sale 0.75 757 568 223,227 Apr 23 04:15 PM Miller Edward General Counsel Apr 19 '24 Sale 0.75 626 470 223,984 Apr 23 04:15 PM Brainard Diana Chief Executive Officer Apr 19 '24 Sale 0.75 9,601 7,207 802,935 Apr 23 04:15 PM Sinha Vikas See Remarks Apr 22 '24 Sale 0.75 1,857 1,393 1,138,096 Apr 23 04:15 PM Sinha Vikas See Remarks Apr 19 '24 Sale 0.75 1,521 1,142 1,139,953 Apr 23 04:15 PM Miller Edward General Counsel Apr 02 '24 Sale 0.77 368 284 224,610 Apr 04 04:15 PM Brainard Diana Chief Executive Officer Apr 02 '24 Sale 0.77 1,533 1,183 812,536 Apr 04 04:15 PM Hagen Brett R Chief Accounting Officer Apr 02 '24 Sale 0.77 281 217 78,572 Apr 04 04:15 PM Sinha Vikas See Remarks Apr 02 '24 Sale 0.77 885 683 1,141,474 Apr 04 04:15 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
